Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A randomized, double-blind, placebo-controlled phase3 clinical trial of OCV-C01 for patients with pancreatic cancer refractory to standard therapy

Next Previous
Trial Profile

A randomized, double-blind, placebo-controlled phase3 clinical trial of OCV-C01 for patients with pancreatic cancer refractory to standard therapy

Status: Discontinued
Phase of Trial: Phase III

Latest Information Update: 16 May 2016

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs OCV C01 (Primary)
  • Indications Adenocarcinoma; Pancreatic ductal carcinoma
  • Focus Registrational; Therapeutic Use
  • Acronyms COMPETE-PC; R000008586
  • Sponsors OncoTherapy Science

Most Recent Events

  • 20 Dec 2013 Primary endpoint 'Overall-survival' has not been met.
  • 20 Dec 2013 Status changed from recruiting to discontinued, as reported in an OncoTherapy Science media release.
  • 19 Dec 2013 Results published in the Media Release.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top